Hepatitis Monthly

Published by: Kowsar

Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience

Ibrahim Halil Bahcecioglu 1 , * , Murat Ispiroglu 1 , Ulvi Demirel 1 and Mehmet Yalniz 1
Authors Information
1 Department of Gastroenterology, Faculty of Medicine, Firat University, Elazig, Turkey
Article information
  • Hepatitis Monthly: March 01, 2015, 15 (3); e24366
  • Published Online: March 31, 2015
  • Article Type: Research Article
  • Received: October 6, 2014
  • Revised: February 6, 2015
  • Accepted: February 21, 2015
  • DOI: 10.5812/hepatmon.24366

To Cite: Bahcecioglu I H, Ispiroglu M, Demirel U, Yalniz M. Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience, Hepat Mon. 2015 ;15(3):e24366. doi: 10.5812/hepatmon.24366.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
References
  • 1. Manesis EK, Schina M, Le Gal F, Agelopoulou O, Papaioannou C, Kalligeros C, et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther. 2007; 12(3): 381-8[PubMed]
  • 2. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977; 18(12): 997-1003[PubMed]
  • 3. Lau JY, Smith HM, Chaggar K, Hansen LJ, Portmann BC, Alexander GJ, et al. Significance of IgM anti-hepatitis D virus (HDV) in chronic HDV infection. J Med Virol. 1991; 33(4): 273-6[PubMed]
  • 4. Koytak ES, Yurdaydin C, Glenn JS. Hepatitis d. Curr Treat Options Gastroenterol. 2007; 10(6): 456-63[PubMed]
  • 5. Degertekin H, Yalcin K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turk J Gastroenterol. 2006; 17(1): 25-34[PubMed]
  • 6. Alvarado-Mora MV, Locarnini S, Rizzetto M, Pinho JR. An update on HDV: virology, pathogenesis and treatment. Antivir Ther. 2013; 18(3 Pt B): 541-8[DOI][PubMed]
  • 7. Rizzetto M. Hepatitis D: the comeback? Liver Int. 2009; 29 Suppl 1: 140-2[DOI][PubMed]
  • 8. Degertekin H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008; 28(4): 494-8[DOI][PubMed]
  • 9. Gunsar F. Treatment of delta hepatitis. Expert Rev Anti Infect Ther. 2013; 11(5): 489-98[DOI][PubMed]
  • 10. Berk L, de Man RA, Housset C, Berthelot P, Schalm SW. Alpha lymphoblastoid interferon and acyclovir for chronic hepatitis delta. Prog Clin Biol Res. 1991; 364: 411-20[PubMed]
  • 11. Garripoli A, Di Marco V, Cozzolongo R, Costa C, Smedile A, Fabiano A, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. 1994; 14(3): 154-7[PubMed]
  • 12. Rosina F, Conoscitore P, Smedile A, Mangia A, Borghesio E, Martinotti R, et al. Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study. Dig Liver Dis. 2002; 34(4): 285-9[PubMed]
  • 13. Yurdaydin C, Bozkaya H, Gurel S, Tillmann HL, Aslan N, Okcu-Heper A, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol. 2002; 37(2): 266-71[PubMed]
  • 14. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005; 22(3): 227-32[DOI][PubMed]
  • 15. Rizzetto M. Hepatitis D: clinical features and therapy. Dig Dis. 2010; 28(1): 139-43[DOI][PubMed]
  • 16. Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014; 16(1): 365[DOI][PubMed]
  • 17. Rosina F, Saracco G, Lattore V, Quartarone V, Rizzetto M, Verme G, et al. Alpha 2 recombinant interferon in the treatment of chronic hepatitis delta virus (HDV) hepatitis. Prog Clin Biol Res. 1987; 234: 299-303[PubMed]
  • 18. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006; 44(3): 713-20[DOI][PubMed]
  • 19. Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006; 26(7): 805-10[DOI][PubMed]
  • 20. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011; 364(4): 322-31[DOI][PubMed]
  • 21. Karaca C, Soyer OM, Baran B, Ormeci AC, Gokturk S, Aydin E, et al. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther. 2013; 18(4): 561-6[DOI][PubMed]
  • 22. Samiullah S, Bikharam D. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol. 2012; 18(40): 5793-8[DOI][PubMed]
  • 23. Gulsun S, Tekin R, Bozkurt F. Treatment of chronic delta hepatitis: a nine-year retrospective analysis. Hepat Mon. 2011; 11(9): 731-5[DOI][PubMed]
  • 24. Ormeci N, Bolukbas F, Erden E, Coban S, Ekiz F, Erdem H, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology. 2011; 58(110-111): 1648-53[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments